2 Things Novavax Must Do to Be a Monster Comeback Stock
Most stocks move higher when there's good news. And then there's Novavax (NASDAQ: NVAX).
Last week, the U.S. Food and Drug Administration (FDA) at long last granted Emergency Use Authorization (EUA) to Novavax's COVID-19 vaccine. Instead of rising, though, Novavax's shares plunged 27%.
There are several reasons behind this surprising sell-off, some of which have nothing to do with the FDA's EUA decision. But shareholders who have stuck with Novavax through a lot of drama are understandably quite frustrated.
Source Fool.com
